Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL2301863 | 1.00 | CA4 (0.39) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL6536657 | 1.00 | CA4 (0.39) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL904478 | 1.00 | CA4 (0.39) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL904703 | 0.95 | — | — | |
| Bicarbonate SCHEMBL2304976 | 0.95 | — | — | |
| Bicarbonate SCHEMBL2432323 | 0.95 | CA4 (0.42) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL570556 | 0.95 | CA4 (0.42) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL81419 | 0.95 | CA4 (0.42) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL2050659 | 0.95 | CA4 (0.42) | CA4CA1FAHD1LMNAMEN1 | |
| Bicarbonate SCHEMBL3732974 | 0.95 | CA4 (0.42) | CA4CA1FAHD1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112280936-A | Aluminum-manganese-iron alloy steelmaking deoxidizer and preparation method and application thereof | 济南鲍德炉料有限公司 | 2021-01-29 | — | — | CN | claimed |
| WO-2020056036-A1 | COMPOSITIONS FOR TREATING GASTROESOPHAGEAL REFLUX AND BARRETT'S ESOPHAGUS | STRONTIUM NEUROGENICS INC. (US) | 2020-03-19 | — | — | WO | claimed |
| CN-109580611-A | A kind of Ion identification method of almagate suspension | 扬州洋制药有限公司 | 2019-04-05 | — | — | CN | claimed |
| CN-109498586-A | A kind of almagate chewable tablets and preparation method thereof | 扬州洋制药有限公司 | 2019-03-22 | — | — | CN | claimed |
| CN-109398829-A | A kind of packaging process of almagate suspension | 扬州洋制药有限公司 | 2019-03-01 | — | — | CN | claimed |
| CN-106074596-B | A kind of suspension method of almagate | 扬州洋制药有限公司 | 2018-10-19 | — | — | CN | claimed |
| CN-105911057-B | A kind of method of quality control of almagate suspension | 扬州洋制药有限公司 | 2018-10-19 | — | — | CN | claimed |
| CN-108159072-A | The preparation process of almagate | 上海裕英生物医药科技有限公司 | 2018-06-15 | — | — | CN | claimed |
| CN-106074596-A | A kind of suspendible method of almagate | 扬州洋制药有限公司 | 2016-11-09 | — | — | CN | claimed |
| US-20160250253-A1 | STRONTIUM-CONTAINING COMPLEXES FOR TREATING GASTROESOPHAGEAL REFLUX AND BARRETT'S ESOPHAGUS | GALLEON LABS LLC | 2016-09-01 | — | — | US | claimed |
| CN-105911057-A | Quality control method of almagate suspension | 扬州洋制药有限公司 | 2016-08-31 | — | — | CN | claimed |
| WO-2015048153-A1 | STRONTIUM-CONTAINING COMPLEXES FOR TREATING GASTROESOPHAGEAL REFLUX AND BARRETT'S ESOPHAGUS | Cosmederm Bioscience, Inc. (US) | 2015-04-02 | — | — | WO | claimed |
| CN-104163443-A | Preparation method of Almagate serving as antiacid | BEIJING HECHENG XIANFENG PHARMACEUTICAL TECHNOLOGY CO LTD | 2014-11-26 | — | — | CN | claimed |
| CN-103432091-A | Improved-performance tablet and preparation method thereof | ZHONG SHUGUANG | 2013-12-11 | — | — | CN | claimed |
| CN-101919822-B | Tablet with improved combination properties and preparation method thereof | ZHONG SHUGUANG | 2013-10-23 | — | — | CN | claimed |
| EP-0486863-B1 | Antiacid compositions with prolonged gastric residence time | BAYER AG (DE) | 1995-08-30 | — | — | EP | claimed |
| US-5213794-A | Calcium polycarbophil, anionic polymer binder | BAYER AKTIENGESELLSCHAFT (DE) | 1993-05-25 | — | — | US | claimed |
| EP-0338861-B1 | ANTACID COMPOSITIONS WITH PROLONGED GASTRIC RESIDENCE TIME | WALTON S.A. (ES) | 1993-01-20 | — | — | EP | claimed |
| EP-0338861-A2 | Antacid compositions with prolonged gastric residence time | WALTON S.A. (ES) | 1989-10-25 | — | — | EP | claimed |
| JP-2015025-A | — | — | None | — | — | JP | disclosed |
| JP-4290816-A | — | — | None | — | — | JP | disclosed |
| EP-4543449-A1 | DOSAGE REGIMEN FOR AXL INHIBITOR | BerGenBio ASA (NO) | 2025-04-30 | — | — | EP | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| WO-2023247769-A1 | DOSAGE REGIMEN FOR AXL INHIBITOR | BERGENBIO ASA (NO) | 2023-12-28 | — | — | WO | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| US-20230190662-A1 | Efficacy of a Gastro-Retentive Bile Acid Sequestrant Dosage Form | IRONWOOD PHARMACEUTICALS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| CN-116239137-A | Preparation method of low-sodium aluminum magnesium alloy | 湖南九典宏阳制药有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2023275642-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTON PUMP INHIBITOR FOR GASTRIC ABSORPTION | LABORATORIOS LIOMONT, S.A. DE C.V. (MX) | 2023-01-05 | — | — | WO | disclosed |
| US-20220370367-A1 | Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid Sequestrant | IRONWOOD PHARMACEUTICALS INC (US) | 2022-11-24 | — | — | US | disclosed |
| US-11446346-B2 | Gastroretentive sustained release formulations of Bergenia ciliata | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-09-20 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4041199-A1 | ESSENTIALLY SODIUM-FREE EFFERVESCENT SOLID PHARMACEUTICAL COMPOSITIONS | Intas Pharmaceuticals Ltd. (IN) | 2022-08-17 | — | — | EP | disclosed |
| US-20220226368-A1 | ESSENTIALLY SODIUM-FREE EFFERVESCENT SOLID PHARMACEUTICAL COMPOSITIONS | INTAS PHARMACEUTICALS LIMTED (IN) | 2022-07-21 | — | — | US | disclosed |
| EP-3991719-A1 | GASTRO-RETENTIVE SUSTAINED-RELEASE ORAL DOSAGE FORM OF A BILE ACID SEQUESTRANT | Ironwood Pharmaceuticals, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220110876-A1 | Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid Sequestrant | IRONWOOD PHARMACEUTICALS INC (US) | 2022-04-14 | — | — | US | disclosed |
| CN-114306678-A | Method for sterilizing aluminum-magnesium suspension | 扬州一洋制药有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220031736-A1 | USE OF ANIONIC CLAY IN PREPARING LEAD-REMOVING MEDICINE | MA DEJUN (CN) | 2022-02-03 | — | — | US | disclosed |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FIRST WAVE BIO, INC. | 2021-12-30 | — | — | US | disclosed |
| EP-2945614-B1 | GASTRO-RETENTIVE SUSTAINED-RELEASE ORAL DOSAGE FORM OF A BILE ACID SEQUESTRANT | IRONWOOD PHARMACEUTICALS INC (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2021188564-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20210114973-A1 | PHARMACEUTICAL FORMULATIONS | FIRST WAVE BIO, INC. | 2021-04-22 | — | — | US | disclosed |
| WO-2021076922-A1 | PHARMACEUTICAL FORMULATIONS | FIRST WAVE BIO, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-10980756-B1 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| WO-2021064636-A1 | ESSENTIALLY SODIUM-FREE EFFERVESCENT SOLID PHARMACEUTICAL COMPOSITIONS | INTAS PHARMACEUTICALS LTD. (IN) | 2021-04-08 | — | — | WO | disclosed |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10905666-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| CN-112280936-A | Aluminum-manganese-iron alloy steelmaking deoxidizer and preparation method and application thereof | 济南鲍德炉料有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-20210015754-A1 | GASTRO-RETENTIVE SUSTAINED-RELEASE ORAL DOSAGE FORM OF A BILE ACID SEQUESTRANT | IRONWOOD PHARMACEUTICALS INC (US) | 2021-01-21 | — | — | US | disclosed |
| US-10849867-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2020211708-A1 | USE OF ANIONIC CLAY IN PREPARING LEAD-REMOVING MEDICAMENT | 马德君 | 2020-10-22 | — | — | WO | disclosed |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200316150-A1 | GASTRORETENTIVE SUSTAINED RELEASE FORMULATIONS OF BERGENIA CILIATA | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-10-08 | — | — | US | disclosed |
| US-10772854-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200268694-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-08-27 | — | — | US | disclosed |
| EP-3697388-A1 | GASTRORETENTIVE SUSTAINED RELEASE FORMULATIONS OFBERGENIA CILIATA | Council Of Scientific & Industrial Research (IN) | 2020-08-26 | — | — | EP | disclosed |
| US-10743604-B2 | Articles of manufacture releasing an active ingredient | NNTT TECH INC. (CA) | 2020-08-18 | — | — | US | disclosed |
| US-10744103-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200197339-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-06-25 | — | — | US | disclosed |
| EP-2983657-B1 | NADOLOL FORMULATIONS FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISORDERS | NUMEDII INC (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3654953-A1 | EFFICACY OF A GASTRO-RETENTIVE BILE ACID SEQUESTRANT DOSAGE FORM | Ironwood Pharmaceuticals, Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200138854-A1 | Method of Detecting and Quantifying Bile Acid from Saliva | IRONWOOD PHARMACEUTICALS INC (US) | 2020-05-07 | — | — | US | disclosed |
| EP-3628307-A1 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | Ironwood Pharmaceuticals, Inc. (US) | 2020-04-01 | — | — | EP | disclosed |
| WO-2020056036-A1 | COMPOSITIONS FOR TREATING GASTROESOPHAGEAL REFLUX AND BARRETT'S ESOPHAGUS | STRONTIUM NEUROGENICS INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2019199100-A1 | PHARMACEUTICAL COMPOSITION | 보령제약 주식회사 | 2019-10-17 | — | — | WO | disclosed |
| CN-110327370-A | Layered compound is used to prepare the purposes for driving lead drug | 马德君 | 2019-10-15 | — | — | CN | disclosed |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | MONTERESEARCH S.R.L. (IT) | 2019-10-03 | — | — | US | disclosed |
| EP-2124884-B1 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | IRONWOOD PHARMACEUTICALS INC (US) | 2019-07-10 | — | — | EP | disclosed |
| CN-109809454-A | A kind of purifying process of colloidal compound | 湖南九典宏阳制药有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-109809454-A | A kind of purifying process of colloidal compound | 湖南九典宏阳制药有限公司 | 2019-05-28 | — | — | CN | disclosed |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| WO-2019077620-A1 | GASTRORETENTIVE SUSTAINED RELEASE FORMULATIONS OF BERGENIA CILIATA | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-04-25 | — | — | WO | disclosed |
| CN-109580611-A | A kind of Ion identification method of almagate suspension | 扬州洋制药有限公司 | 2019-04-05 | — | — | CN | disclosed |
| CN-109580611-A | A kind of Ion identification method of almagate suspension | 扬州洋制药有限公司 | 2019-04-05 | — | — | CN | disclosed |
| CN-109580611-A | A kind of Ion identification method of almagate suspension | 扬州洋制药有限公司 | 2019-04-05 | — | — | CN | disclosed |
| CN-109562137-A | Methods and compositions for treating conditions associated with abnormal inflammatory responses | 第波生物公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109498586-A | A kind of almagate chewable tablets and preparation method thereof | 扬州洋制药有限公司 | 2019-03-22 | — | — | CN | disclosed |
| CN-109498586-A | A kind of almagate chewable tablets and preparation method thereof | 扬州洋制药有限公司 | 2019-03-22 | — | — | CN | disclosed |
| CN-109498586-A | A kind of almagate chewable tablets and preparation method thereof | 扬州洋制药有限公司 | 2019-03-22 | — | — | CN | disclosed |
| CN-109459543-A | A method of the test external Antacid effectiveness of inorganic antacid containing magnesium | 马德君 | 2019-03-12 | — | — | CN | disclosed |
| CN-109398829-A | A kind of packaging process of almagate suspension | 扬州洋制药有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-109398829-A | A kind of packaging process of almagate suspension | 扬州洋制药有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-109398829-A | A kind of packaging process of almagate suspension | 扬州洋制药有限公司 | 2019-03-01 | — | — | CN | disclosed |
| EP-3434264-A1 | MICROPARTICLE FOR RELEASING AN ACITVE AGENT | Biomod Concepts Inc. (CA) | 2019-01-30 | — | — | EP | disclosed |
| WO-2019018639-A1 | METHOD OF DETECTING AND QUANTIFYING BILE ACID FROM SALIVA | IRONWOOD PHARMACEUTICALS, INC. (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2019018656-A1 | EFFICACY OF A GASTRO-RETENTIVE BILE ACID SEQUESTRANT DOSAGE FORM | IRONWOOD PHARMACEUTICALS, INC. (US) | 2019-01-24 | — | — | WO | disclosed |
| EP-2317984-B1 | ARTICLES OF MANUFACTURE RELEASING AN ACTIVE INGREDIENT | BIOMOD CONCEPTS INC (CA) | 2018-10-31 | — | — | EP | disclosed |
| CN-106074596-B | A kind of suspension method of almagate | 扬州洋制药有限公司 | 2018-10-19 | — | — | CN | disclosed |
| CN-105911057-B | A kind of method of quality control of almagate suspension | 扬州洋制药有限公司 | 2018-10-19 | — | — | CN | disclosed |
| CN-106074596-B | A kind of suspension method of almagate | 扬州洋制药有限公司 | 2018-10-19 | — | — | CN | disclosed |
| CN-105911057-B | A kind of method of quality control of almagate suspension | 扬州洋制药有限公司 | 2018-10-19 | — | — | CN | disclosed |
| CN-105911057-B | A kind of method of quality control of almagate suspension | 扬州洋制药有限公司 | 2018-10-19 | — | — | CN | disclosed |
| CN-106074596-B | A kind of suspension method of almagate | 扬州洋制药有限公司 | 2018-10-19 | — | — | CN | disclosed |
| US-20180235878-A1 | COMPOSITIONS COMPRISING FILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3344274-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Bio, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| CN-108159072-A | The preparation process of almagate | 上海裕英生物医药科技有限公司 | 2018-06-15 | — | — | CN | disclosed |
| CN-108159072-A | The preparation process of almagate | 上海裕英生物医药科技有限公司 | 2018-06-15 | — | — | CN | disclosed |
| CN-108159072-A | The preparation process of almagate | 上海裕英生物医药科技有限公司 | 2018-06-15 | — | — | CN | disclosed |
| US-20180146735-A1 | Articles Of Manufacture Releasing An Active Ingredient | NNTT TECH INC. (CA) | 2018-05-31 | — | — | US | disclosed |
| CN-108057028-A | The Entogastric lingering peroral dosage form of the enteric coating of tablet form and its application and pharmaceutical composition | 铁木医药有限公司 | 2018-05-22 | — | — | CN | disclosed |
| US-9883710-B2 | Articles of manufacture releasing an active ingredient | BIOMOD CONCEPTS INC. (CA) | 2018-02-06 | — | — | US | disclosed |
| US-9861154-B2 | Articles of manufacture releasing an active ingredient | BIOMOD COLLECTION INC. (CA) | 2018-01-09 | — | — | US | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-20170290767-A1 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-12 | — | — | US | disclosed |
| CN-104383422-B | It is a kind of to be used to treat Chinese patent drug of chronic gastropathy and preparation method thereof | 中国人民解放军第五医院 | 2017-09-29 | — | — | CN | disclosed |
| US-20170266116-A1 | GASTRO-RETENTIVE SUSTAINED-RELEASE ORAL DOSAGE FORM OF A BILE ACID SEQUESTRANT | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9730483-B2 | Articles of manufacture releasing an active ingredient | BIOMOD CONCEPTS INC. (CA) | 2017-08-15 | — | — | US | disclosed |
| US-9642809-B2 | Controlled release pharmaceutical compositions for prolonged effect | EGALET LTD. (GB) | 2017-05-09 | — | — | US | disclosed |
| EP-3162371-A1 | A COMPOSITION COMPRISING SIMETHICONE, GASTRIC ACID-NEUTRALIZING SUBSTANCES AND GASTRIC ENZYME(S) (E.G. PANCREATINE) FOR USE IN THE TREATMENT OF DIGESTIVE DISORDERS | Taciak, Przemyslaw (PL) | 2017-05-03 | — | — | EP | disclosed |
| WO-2017040864-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Biopharma (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9499535-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| CN-106074596-A | A kind of suspendible method of almagate | 扬州洋制药有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-106074596-A | A kind of suspendible method of almagate | 扬州洋制药有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-106074596-A | A kind of suspendible method of almagate | 扬州洋制药有限公司 | 2016-11-09 | — | — | CN | disclosed |
| US-20160303133-A1 | TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS | NUMEDII, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| CN-105920385-A | Traditional Chinese medicinal preparation for treating duodenal ulcer in radiology department and preparation method of traditional Chinese medicinal preparation | 张桂臣 | 2016-09-07 | — | — | CN | disclosed |
| US-20160250253-A1 | STRONTIUM-CONTAINING COMPLEXES FOR TREATING GASTROESOPHAGEAL REFLUX AND BARRETT'S ESOPHAGUS | GALLEON LABS LLC | 2016-09-01 | — | — | US | disclosed |
| CN-105911057-A | Quality control method of almagate suspension | 扬州洋制药有限公司 | 2016-08-31 | — | — | CN | disclosed |
| CN-105911057-A | Quality control method of almagate suspension | 扬州洋制药有限公司 | 2016-08-31 | — | — | CN | disclosed |
| CN-105911057-A | Quality control method of almagate suspension | 扬州洋制药有限公司 | 2016-08-31 | — | — | CN | disclosed |
| EP-2699572-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| US-20160051577-A1 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-25 | — | — | US | disclosed |
| EP-2983657-A1 | TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS | Numedii, Inc. (US) | 2016-02-17 | — | — | EP | disclosed |
| CN-105338958-A | Gastric retentive sustained release oral dosage forms of bile acid sequestrants | IRONWOOD PHARMACEUTICALS INC | 2016-02-17 | — | — | CN | disclosed |
| US-20160015644-A1 | GASTRO-RETENTIVE SUSTAINED-RELEASE ORAL DOSAGE FORM OF A BILE ACID SEQUESTRANT | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| CN-105263482-A | Treatment of gastrointestinal and other disorders | NUMEDII INC | 2016-01-20 | — | — | CN | disclosed |
| US-9205094-B2 | Compositions comprising bile acid sequestrants for treating esophageal disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2945614-A1 | GASTRO-RETENTIVE SUSTAINED-RELEASE ORAL DOSAGE FORM OF A BILE ACID SEQUESTRANT | Ironwood Pharmaceuticals, Inc. (US) | 2015-11-25 | — | — | EP | disclosed |
| CN-105055309-A | Hydroxy-aluminum montmorillonite suspension as well as preparation method and application thereof | SHANDONG SBOND PHARMACEUTICAL CO LTD | 2015-11-18 | — | — | CN | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| CN-102099015-B | Articles of manufacture releasing an active ingredient | BIOMOD CONCEPTS INC | 2015-05-06 | — | — | CN | disclosed |
| WO-2015048153-A1 | STRONTIUM-CONTAINING COMPLEXES FOR TREATING GASTROESOPHAGEAL REFLUX AND BARRETT'S ESOPHAGUS | Cosmederm Bioscience, Inc. (US) | 2015-04-02 | — | — | WO | disclosed |
| CN-104383422-A | Chinese patent medicine for treating chronic gastritis and preparation method thereof | FIFTH HOSPITAL OF PEOPLE S LIBERATION ARMY | 2015-03-04 | — | — | CN | disclosed |
| US-20150024048-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | EGALET LIMITED (GB) | 2015-01-22 | — | — | US | disclosed |
| EP-1978935-B1 | COATED FORMULATIONS | LEK PHARMACEUTICALS (SI) | 2015-01-07 | — | — | EP | disclosed |
| US-20140377361-A1 | STABLE METAL ION-LIPID POWDERED PHARMACEUTICAL COMPOSITIONS FOR DRUG DELIVERY | NOVARTIS AG (CH) | 2014-12-25 | — | — | US | disclosed |
| CN-104163443-A | Preparation method of Almagate serving as antiacid | BEIJING HECHENG XIANFENG PHARMACEUTICAL TECHNOLOGY CO LTD | 2014-11-26 | — | — | CN | disclosed |
| CN-104163443-A | Preparation method of Almagate serving as antiacid | BEIJING HECHENG XIANFENG PHARMACEUTICAL TECHNOLOGY CO LTD | 2014-11-26 | — | — | CN | disclosed |
| CN-104163443-A | Preparation method of Almagate serving as antiacid | BEIJING HECHENG XIANFENG PHARMACEUTICAL TECHNOLOGY CO LTD | 2014-11-26 | — | — | CN | disclosed |
| US-8877162-B2 | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| WO-2014165823-A1 | TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS | NUMEDII, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-8821928-B2 | Controlled release pharmaceutical compositions for prolonged effect | EGALET LTD. (GB) | 2014-09-02 | — | — | US | disclosed |
| WO-2014113377-A1 | GASTRO-RETENTIVE SUSTAINED-RELEASE ORAL DOSAGE FORM OF A BILE ACID SEQUESTRANT | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
| CN-103492389-A | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors | ORIGENIS GMBH | 2014-01-01 | — | — | CN | disclosed |
| CN-103432091-A | Improved-performance tablet and preparation method thereof | ZHONG SHUGUANG | 2013-12-11 | — | — | CN | disclosed |
| CN-102018962-B | Polymer intensifier in controlled release preparation | ZHONG SHUGUANG | 2013-11-06 | — | — | CN | disclosed |
| CN-101919822-B | Tablet with improved combination properties and preparation method thereof | ZHONG SHUGUANG | 2013-10-23 | — | — | CN | disclosed |
| US-20130129660-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GASTROINTESTINAL DISORDERS AND GERD-RELATED RESPIRATORY DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130095153-A1 | STABLE METAL ION-LIPID POWDERED PHARMACEUTICAL COMPOSITIONS FOR DRUG DELIVERY | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-8349294-B2 | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| EP-2478895-A2 | Compositions for treating esophageal disorders | Ironwood Pharmaceuticals, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2478894-A2 | Compositions for treating esophageal disorders | Ironwood Pharmaceuticals, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| CN-101797253-B | Bergenin and cetirizine dihydrochloride compound oral administration preparation | UNIV SICHUAN | 2011-07-20 | — | — | CN | disclosed |
| CN-102099015-A | Articles of manufacture releasing an active ingredient | BIOMOD INC | 2011-06-15 | — | — | CN | disclosed |
| US-20110129433-A1 | Compositions and Methods for Treating or Preventing Gastrointestinal Disorders and GERD-Related Respiratory Disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2317984-A1 | ARTICLES OF MANUFACTURE RELEASING AN ACTIVE INGREDIENT | Biomod Concepts Inc. (CA) | 2011-05-11 | — | — | EP | disclosed |
| CN-102018962-A | Polymer intensifier in controlled release preparation | SHUGUANG ZHONG | 2011-04-20 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20110082076-A1 | STABLE METAL ION-LIPID POWDERED PHARMACEUTICAL COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110010817-A1 | Articles of Manufacture Releasing an Active Ingredient | BIOMOD COLLECTION INC. (CA) | 2011-01-20 | — | — | US | disclosed |
| US-7871598-B1 | exhibit improved stability and dispersability over the shelf life of the composition; microparticles are simple to produce without the need of the formation of an emulsion or the use of an oil as a blowing agent | NOVARTIS AG (CH) | 2011-01-18 | — | — | US | disclosed |
| EP-1682097-B1 | NON-TABLETTED, CHEWABLE, INDIVIDUALLY DOSED ADMINISTRATION FORMS | ALMIRALL SA (ES) | 2010-12-22 | — | — | EP | disclosed |
| CN-101919803-A | A kind of controlled release preparation | SHUGUANG ZHONG | 2010-12-22 | — | — | CN | disclosed |
| CN-101919822-A | Tablet with improved combination properties and preparation method thereof | SHUGUANG ZHONG | 2010-12-22 | — | — | CN | disclosed |
| US-20100305209-A1 | Articles of Manufacture Releasing an Active Ingredient | BIOMOD COLLECTION INC. (CA) | 2010-12-02 | — | — | US | disclosed |
| US-20100239667-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | EGALET A/S (DK) | 2010-09-23 | — | — | US | disclosed |
| US-20100226947-A1 | ARTICLES OF MANUFACTURE RELEASING AN ACTIVE INGREDIENT | BIOMOD INC. (CA) | 2010-09-09 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| CN-101797253-A | Bergenin and cetirizine dihydrochloride compound oral administration preparation | UNIV SICHUAN | 2010-08-11 | — | — | CN | disclosed |
| US-20100179235-A1 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | IRONWOOD PHARMACEUTICALS (US) | 2010-07-15 | — | — | US | disclosed |
| EP-2201952-A1 | Omeprazole dosage forms and their use | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-2155167-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | Egalet A/S (DK) | 2010-02-24 | — | — | EP | disclosed |
| WO-2010006442-A1 | ARTICLES OF MANUFACTURE RELEASING AN ACTIVE INGREDIENT | BIOMOD INC. (CA) | 2010-01-21 | — | — | WO | disclosed |
| WO-2009158625-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GASTROINTESTINAL DISORDERS AND GERD-RELATED RESPIRATORY DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| EP-2124884-A2 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | Ironwood Pharmaceuticals, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| CN-100563686-C | A kind of gastric floating capsule of ' Zuo Jin Wan ' and preparation method thereof | UNIV NANJING TRAD CHINESE MED (CN) | 2009-12-02 | — | — | CN | disclosed |
| WO-2008148798-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | EGALET A/S (DK) | 2008-12-11 | — | — | WO | disclosed |
| EP-1978935-A1 | COATED FORMULATIONS | LEK Pharmaceuticals D.D. (SI) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008080092-A2 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153880-A1 | PAN-ALPHA-2 RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153881-A1 | ALPHA-2B RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20070239104-A1 | Anti acid G/tube pad | FEERRAR ANGELA C | 2007-10-11 | — | — | US | disclosed |
| WO-2007082770-A1 | COATED FORMULATIONS | LEK PHARMACEUTICALS D.D. (SI) | 2007-07-26 | — | — | WO | disclosed |
| EP-1810668-A1 | Coated formulations containing tolterodine tartrate | LEK Pharmaceuticals D.D. (SI) | 2007-07-25 | — | — | EP | disclosed |
| US-20070134318-A1 | Non-tabletted, chewable, individually dosed administration forms | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-06-14 | — | — | US | disclosed |
| CN-1951443-A | Gastric floating capsule of 'Zuo Jin Wan' and preparation method thereof | UNIV NANJING TRAD CHINESE MED (CN) | 2007-04-25 | — | — | CN | disclosed |
| US-7144474-B1 | Method of binding particles to binder treated fibers | WEYERHAEUSER CO. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1682097-A2 | NON-TABLETTED, CHEWABLE, INDIVIDUALLY DOSED ADMINISTRATION FORMS | Almirall Prodesfarma, S.A. (ES) | 2006-07-26 | — | — | EP | disclosed |
| EP-1660043-A2 | IMMEDIATE-RELEASE FORMULATION OF ACID-LABILE PHARMACEUTICAL COMPOSITIONS | The Curators of the University of Missouri (US) | 2006-05-31 | — | — | EP | disclosed |
| US-7018490-B2 | Method of binding binder treated particles to fibers | WEYERHAEUSER COMPANY (US) | 2006-03-28 | — | — | US | disclosed |
| CN-1735344-A | Novel substituted benzimidazole dosage forms and methods of use thereof | UNIV MISSOURI (US) | 2006-02-15 | — | — | CN | disclosed |
| EP-0655971-B2 | METHOD OF BINDING PARTICLES TO FIBERS | WEYERHAEUSER CO (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1414452-A4 | NOVEL SUBSTITUTED BENZIMIDAZOLE DOSAGE FORMS AND METHOD OF USING SAME | UNIV MISSOURI (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1538908-A2 | NOVEL SUBSTITUTED BENZIMIDAZOLE DOSAGE FORMS AND METHOD OF USING SAME | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005048975-A1 | NON-TABLETTED, CHEWABLE, INDIVIDUALLY DOSED ADMINISTRATION FORMS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005048974-A2 | NON-TABLETTED, CHEWABLE, INDIVIDUALLY DOSED ADMINISTRATION FORMS | ALMIRALL PRODESFARMA, S.A. (ES) | 2005-06-02 | — | — | WO | disclosed |
| US-20050112193-A1 | pH buffering agent and a controlled-release component containing an acid-labile proton pump inhibitor such as omeprazole which is protected from acid degradation in the gastrointestinal fluid by the buffer | BAUSCH HEALTH AMERICAS, INC. | 2005-05-26 | — | — | US | disclosed |
| US-20050054682-A1 | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same | UNIVERSITY OF MISSOURI-COLUMBIA | 2005-03-10 | — | — | US | disclosed |
| WO-2005009381-A2 | IMMEDIATE-RELEASE FORMULATION OF ACID-LABILE PHARMACEUTICAL COMPOSITIONS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050004171-A1 | Novel substituted benzimidazole dosage forms and method of using same | CURATORS OF THE UNIVERSITY OF MISSOURI | 2005-01-06 | — | — | US | disclosed |
| CN-1551768-A | Novel substituted benzimidazole dosage forms and methods of use thereof | ����˹���ѧ���»� | 2004-12-01 | — | — | CN | disclosed |
| EP-1219744-B1 | Particle binders | WEYERHAEUSER CO (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040171646-A1 | Novel substituted benzimidazole dosage forms and method of using same | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2004-09-02 | — | — | US | disclosed |
| US-6743820-B2 | ADMINISTERING TO THE EPITHELIUM AN EFFECTIVE AMOUNT OF AN AGENT COMPRISING: A) AT LEAST ONE AROMATIC GROUP; B) AT LEAST ONE SULFATE OR METALSULFATE GROUP AND C) A SUBSTITUENT GROUPS ON THE RING | UNIVERSITY OF TOLEDO | 2004-06-01 | — | — | US | disclosed |
| EP-1414452-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DOSAGE FORMS AND METHOD OF USING SAME | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048896-A1 | Novel substituted benzimidazole dosage forms and method of using same | CURATORS OF THE UNIVERSITY OF MISSOURI | 2004-03-11 | — | — | US | disclosed |
| US-6699885-B2 | Treating gastrointestinal disorders by administering solid oral dosage form of proton pump inhibitor and buffer; buffer inhibits degradation of the proton pump inhibitor by gastric acid; bioavailability | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2004-03-02 | — | — | US | disclosed |
| US-6645535-B2 | Gastrointestinal disorders | WM. WRIGLEY JR. COMPANY | 2003-11-11 | — | — | US | disclosed |
| US-6645988-B2 | Pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors with fast acting buffer; gastric acid stability for enteral administration | CURATORS OF THE UNIVERSITY OF MISSOURI | 2003-11-11 | — | — | US | disclosed |
| US-20030191159-A1 | Novel substituted benzimidazole dosage forms and method of using same | CURATORS OF THE UNIVERSITY OF MISSOURI | 2003-10-09 | — | — | US | disclosed |
| WO-2003061584-A2 | NOVEL SUBSTITUTED BENZIMIDAZOLE DOSAGE FORMS AND METHOD OF USING SAME | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2003-07-31 | — | — | WO | disclosed |
| US-6596103-B1 | Having hydrogen bonding functional sites; nonpolymeric binder comprising propylene glycol; cellulose fibers | WEYERHAEUSER COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-6521087-B2 | Coating the absorber particles with the nonpolymeric glycol binder and activating; hydrogen binding to the cellulosic fibers and forming a web; compressing; easily densifying at a lower external pressure; materials handling | WEYERHAEUSER COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-6521339-B1 | Superabsorbent particles are bound to the wood pulp fibers by the (poly)propylene glycol | WEYERHAEUSER COMPANY | 2003-02-18 | — | — | US | disclosed |
| EP-1282405-A2 | STABLE METAL ION-LIPID POWDERED PHARMACEUTICAL COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | ALLIANCE PHARMACEUTICAL CORPORATION (US) | 2003-02-12 | — | — | EP | disclosed |
| WO-2003009846-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DOSAGE FORMS AND METHOD OF USING SAME | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2003-02-06 | — | — | WO | disclosed |
| EP-0655970-B1 | PARTICLE BINDING TO FIBERS | WEYERHAEUSER CO (US) | 2002-10-09 | — | — | EP | disclosed |
| US-6461553-B1 | Method of binding binder treated particles to fibers | WEYERHAEUSER | 2002-10-08 | — | — | US | disclosed |
| EP-0655971-B1 | METHOD OF BINDING PARTICLES TO FIBERS | WEYERHAEUSER CO (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6425979-B1 | COATING THE ABSORBER PARTICLES WITH THE NONPOLYMERIC GLYCOL BINDER AND ACTIVATING; HYDROGEN BINDING TO THE CELLULOSIC FIBERS AND FORMING A WEB; COMPRESSING; EASILY DENSIFYING AT A LOWER EXTERNAL PRESSURE; MATERIALS HANDLING | WEYERHAEUSER COMPANY | 2002-07-30 | — | — | US | disclosed |
| WO-2002051259-A1 | COATED CHEWING GUM PRODUCTS CONTAINING VARIOUS ANTACIDS | WM. WRIGLEY JR. COMPANY (US) | 2002-07-04 | — | — | WO | disclosed |
| EP-1219744-A1 | Particle binders | WEYERHAEUSER COMPANY (US) | 2002-07-03 | — | — | EP | disclosed |
| EP-1217120-A1 | Particle binding to fibers | WEYERHAEUSER COMPANY (US) | 2002-06-26 | — | — | EP | disclosed |
| US-6391453-B1 | BINDER IS APPLIED TO PARTICLES WHICH ARE THEN COMBINED WITH FIBERS TO BIND THE PARTICLES TO THE FIBERS; THE THREE COMPONENTS ARE CAPABLE OF HYDROGEN BONDING AND/OR COORDINATE COVALENT BONDING TO EACH OTHER; FIBERS ARE EASILY DENSIFIED | WEYERNAEUSER COMPANY | 2002-05-21 | — | — | US | disclosed |
| US-20020052408-A1 | Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-05-02 | — | — | US | disclosed |
| US-20020045646-A1 | Novel substituted benzimidazole dosage forms and method of using same | CURATORS OF THE UNIVERSITY OF MISSOURI | 2002-04-18 | — | — | US | disclosed |
| US-6340411-B1 | Fibrous product containing densifying agent | WEYERHAEUSER COMPANY | 2002-01-22 | — | — | US | disclosed |
| WO-2002004411-A1 | METHODS FOR PROTECTION OF STRATIFIED SQUAMOUS EPITHELIUM AGAINST INJURY BY NOXIOUS SUBSTANCES AND NOVEL AGENTS FOR USE THEREFOR | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001085137-A2 | STABLE METAL ION-LIPID POWDERED PHARMACEUTICAL COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | INHALE THERAPEUTIC SYSTEMS, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
| US-20010021403-A1 | Coated chewing gum products containing various antacids | WM. WRIGLEY JR. COMPANY | 2001-09-13 | — | — | US | disclosed |
| EP-0968133-A1 | BASIC ALUMINIUM MAGNESIUM CARBONATE, METHOD FOR THE PREPARATION THEREOF AND ITS USE AS A PHARMACEUTICAL COMPOSITION FOR TREATING STOMACH ACIDITY | FERRER INTERNACIONAL, S.A. (ES) | 2000-01-05 | — | — | EP | disclosed |
| WO-1999035088-A1 | BASIC ALUMINUM MAGNESIUM CARBONATE, METHOD FOR THE PREPARATION THEREOF AND ITS USE AS A PHARMACEUTICAL COMPOSITION FOR TREATING STOMACH ACIDITY | FERRER INTERNACIONAL, S.A. (ES) | 1999-07-15 | — | — | WO | disclosed |
| EP-0745160-A1 | DENSIFYING AGENTS FOR ENHANCING FIBER DENSIFICATION | WEYERHAEUSER COMPANY (US) | 1996-12-04 | — | — | EP | disclosed |
| WO-1995022655-A1 | DENSIFYING AGENTS FOR ENHANCING FIBER DENSIFICATION | WEYERHAEUSER COMPANY (US) | 1995-08-24 | — | — | WO | disclosed |
| EP-0655971-A4 | PARTICLE BINDERS. | WEYERHAEUSER CO (US) | 1995-07-19 | — | — | EP | disclosed |
| EP-0655970-A4 | PARTICLE BINDING TO FIBERS. | WEYERHAEUSER CO (US) | 1995-07-19 | — | — | EP | disclosed |
| EP-0655971-A1 | PARTICLE BINDERS | WEYERHAEUSER COMPANY (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0655970-A1 | PARTICLE BINDING TO FIBERS | WEYERHAEUSER COMPANY (US) | 1995-06-07 | — | — | EP | disclosed |
| WO-1994004352-A1 | PARTICLE BINDERS | WEYERHAEUSER COMPANY (US) | 1994-03-03 | — | — | WO | disclosed |
| WO-1994004351-A1 | PARTICLE BINDING TO FIBERS | WEYERHAEUSER COMPANY (US) | 1994-03-03 | — | — | WO | disclosed |
| US-5288506-A | Solid antacid granules surrounded by hydrophobic material | WALTON S.A. (ES) | 1994-02-22 | — | — | US | disclosed |
| US-5213794-A | Calcium polycarbophil, anionic polymer binder | BAYER AKTIENGESELLSCHAFT (DE) | 1993-05-25 | — | — | US | disclosed |
| EP-0338861-B1 | ANTACID COMPOSITIONS WITH PROLONGED GASTRIC RESIDENCE TIME | WALTON S.A. (ES) | 1993-01-20 | — | — | EP | disclosed |
| JP-H04290816-A | ANTACID PRODUCT WITH EXTENDED RESIDENCE TIME IN STOMACH | BAYER AG | 1992-10-15 | — | — | JP | disclosed |
| CN-1040287-A | Aluminum cell | ALCAN INT LTD (CA) | 1990-03-07 | — | — | CN | disclosed |
| JP-H0215025-A | ANTACID COMPOSITION WITH PROLONGED GASTRIC RESIDENCE TIME | WALTON SA | 1990-01-18 | — | — | JP | disclosed |
| EP-0338861-A2 | Antacid compositions with prolonged gastric residence time | WALTON S.A. (ES) | 1989-10-25 | — | — | EP | disclosed |
| EP-0338861-A2 | Antacid compositions with prolonged gastric residence time | WALTON S.A. (ES) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (45 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FH, CS, ECHS1 | CA4 626/4885CA1 356/4885FAHD1 144/4885 |
| US-20040048896-A1 | Novel substituted benzimidazole dosage forms and method of using same | ATP6V1H, PGA5, ATP6V1G1 | CA4 2046/4885CA1 4006/4885FAHD1 1637/4885 |
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CA4 623/4885CA1 334/4885FAHD1 141/4885 |
| US-20200197339-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CA4 635/4885CA1 341/4885FAHD1 146/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CA4 623/4885CA1 334/4885FAHD1 141/4885 |
| US-20080153880-A1 | PAN-ALPHA-2 RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | MLNR, GIPR, FFAR2 | CA4 1784/4885CA1 1454/4885FAHD1 2232/4885 |
| US-20200268694-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CA4 635/4885CA1 341/4885FAHD1 146/4885 |
| US-20080153881-A1 | ALPHA-2B RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ADRA2B, GPBAR1, MLNR | CA4 2195/4885CA1 2264/4885FAHD1 2436/4885 |
| US-20210114973-A1 | PHARMACEUTICAL FORMULATIONS | NCSTN, CACNA1B, CACNA1A | CA4 291/4885CA1 275/4885FAHD1 1324/4885 |
| US-10744103-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | CA4 623/4885CA1 334/4885FAHD1 141/4885 |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CA4 635/4885CA1 341/4885FAHD1 146/4885 |
| US-10849867-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | CA4 626/4885CA1 356/4885FAHD1 144/4885 |
| US-20160303133-A1 | TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS | ADRB1, ADRB2, ADRA2B | CA4 3237/4885CA1 4593/4885FAHD1 1861/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | CA4 314/4885CA1 1013/4885FAHD1 455/4885 |
| US-20050112193-A1 | pH buffering agent and a controlled-release component containing an acid-labile proton pump inhibitor such as omeprazole which is protected from acid degradation in the gastrointestinal fluid by the buffer | HRH2, SI, PGA5 | CA4 299/4885CA1 206/4885FAHD1 1441/4885 |
| US-20050004171-A1 | Novel substituted benzimidazole dosage forms and method of using same | ATP6V1H, ATP6V1G1, PGA5 | CA4 1205/4885CA1 2541/4885FAHD1 1561/4885 |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CA4 623/4885CA1 334/4885FAHD1 141/4885 |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | CA4 635/4885CA1 341/4885FAHD1 146/4885 |
| US-20040171646-A1 | Novel substituted benzimidazole dosage forms and method of using same | ATP6V1H, ATP6V1G1, ATP6AP1 | CA4 1270/4885CA1 2792/4885FAHD1 1499/4885 |
| US-20020045646-A1 | Novel substituted benzimidazole dosage forms and method of using same | ATP6V1H, PGA5, ATP6V1G1 | CA4 2046/4885CA1 4006/4885FAHD1 1637/4885 |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | CA4 635/4885CA1 341/4885FAHD1 146/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CA4 228/4885CA1 806/4885FAHD1 406/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | CA4 228/4885CA1 806/4885FAHD1 406/4885 |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | CA4 619/4885CA1 351/4885FAHD1 138/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CA4 180/4885CA1 1097/4885FAHD1 232/4885 |
| US-20050054682-A1 | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same | PGA5, ABCB11, SLC10A2 | CA4 143/4885CA1 626/4885FAHD1 943/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | CA4 180/4885CA1 1097/4885FAHD1 232/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CA4 180/4885CA1 1097/4885FAHD1 232/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | CA4 4842/4885CA1 4834/4885FAHD1 3294/4885 |
| US-20110129433-A1 | Compositions and Methods for Treating or Preventing Gastrointestinal Disorders and GERD-Related Respiratory Disorders | HRH2, GABRB1, GABRB3 | CA4 621/4885CA1 433/4885FAHD1 2340/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | CA4 4880/4885CA1 4868/4885FAHD1 2172/4885 |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CA4 635/4885CA1 341/4885FAHD1 146/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | CA4 980/4885CA1 549/4885FAHD1 220/4885 |
| US-20150024048-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | SI, GIPR, MLN | CA4 1344/4885CA1 334/4885FAHD1 3801/4885 |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CA4 635/4885CA1 341/4885FAHD1 146/4885 |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CA4 635/4885CA1 341/4885FAHD1 146/4885 |
| US-20100239667-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | SI, GIPR, MLN | CA4 1344/4885CA1 334/4885FAHD1 3801/4885 |
| US-20130129660-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GASTROINTESTINAL DISORDERS AND GERD-RELATED RESPIRATORY DISORDERS | HRH2, GABRB1, GABRB3 | CA4 621/4885CA1 433/4885FAHD1 2340/4885 |
| US-10980756-B1 | Methods of treatment | ACE2, ACE, SI | CA4 228/4885CA1 806/4885FAHD1 406/4885 |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CA4 635/4885CA1 341/4885FAHD1 146/4885 |
| US-10772854-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | CA4 626/4885CA1 356/4885FAHD1 144/4885 |
| US-10905666-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | CA4 626/4885CA1 356/4885FAHD1 144/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | CA4 626/4885CA1 356/4885FAHD1 144/4885 |
| US-20020052408-A1 | Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor | HRH2, NR1H4, NCEH1 | CA4 72/4885CA1 251/4885FAHD1 2571/4885 |
| US-20030191159-A1 | Novel substituted benzimidazole dosage forms and method of using same | ATP6V1H, ATP6V1G1, PGA5 | CA4 1205/4885CA1 2541/4885FAHD1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.